151 related articles for article (PubMed ID: 31702627)
21. JCOG0911 INTEGRA study: a randomized screening phase II trial of interferonβ plus temozolomide in comparison with temozolomide alone for newly diagnosed glioblastoma.
Wakabayashi T; Natsume A; Mizusawa J; Katayama H; Fukuda H; Sumi M; Nishikawa R; Narita Y; Muragaki Y; Maruyama T; Ito T; Beppu T; Nakamura H; Kayama T; Sato S; Nagane M; Mishima K; Nakasu Y; Kurisu K; Yamasaki F; Sugiyama K; Onishi T; Iwadate Y; Terasaki M; Kobayashi H; Matsumura A; Ishikawa E; Sasaki H; Mukasa A; Matsuo T; Hirano H; Kumabe T; Shinoura N; Hashimoto N; Aoki T; Asai A; Abe T; Yoshino A; Arakawa Y; Asano K; Yoshimoto K; Shibui S;
J Neurooncol; 2018 Jul; 138(3):627-636. PubMed ID: 29557060
[TBL] [Abstract][Full Text] [Related]
22. Phase 2 Study of Radiation Therapy Plus Low-Dose Temozolomide Followed by Temozolomide and Irinotecan for Glioblastoma: NRG Oncology RTOG Trial 0420.
Lieberman FS; Wang M; Robins HI; Tsien CI; Curran WJ; Werner-Wasik M; Smith RP; Schultz C; Hartford AC; Zhang P; Mehta MP
Int J Radiat Oncol Biol Phys; 2019 Mar; 103(4):878-886. PubMed ID: 30496882
[TBL] [Abstract][Full Text] [Related]
23. Phase II study of hypofractionated radiation therapy in elderly patients with newly diagnosed glioblastoma with poor prognosis.
Navarria P; Pessina F; Cozzi L; Tomatis S; Reggiori G; Simonelli M; Santoro A; Clerici E; Franzese C; Carta G; Conti Nibali M; Bello L; Scorsetti M
Tumori; 2019 Feb; 105(1):47-54. PubMed ID: 30131010
[TBL] [Abstract][Full Text] [Related]
24. Association of patterns of care, prognostic factors, and use of radiotherapy-temozolomide therapy with survival in patients with newly diagnosed glioblastoma: a French national population-based study.
Fabbro-Peray P; Zouaoui S; Darlix A; Fabbro M; Pallud J; Rigau V; Mathieu-Daude H; Bessaoud F; Bauchet F; Riondel A; Sorbets E; Charissoux M; Amelot A; Mandonnet E; Figarella-Branger D; Duffau H; Tretarre B; Taillandier L; Bauchet L
J Neurooncol; 2019 Mar; 142(1):91-101. PubMed ID: 30523606
[TBL] [Abstract][Full Text] [Related]
25. The Prognosis of Anti-Angiogenesis Treatments Combined with Standard Therapy for Newly Diagnosed Glioblastoma: A Meta-Analysis of Randomized Controlled Trials.
Li Y; Hou M; Lu G; Ciccone N; Wang X; Zhang H
PLoS One; 2016; 11(12):e0168264. PubMed ID: 28005980
[TBL] [Abstract][Full Text] [Related]
26. Antiangiogenic therapy for high-grade glioma.
Khasraw M; Ameratunga MS; Grant R; Wheeler H; Pavlakis N
Cochrane Database Syst Rev; 2014 Sep; (9):CD008218. PubMed ID: 25242542
[TBL] [Abstract][Full Text] [Related]
27. Limited role for extended maintenance temozolomide for newly diagnosed glioblastoma.
Gramatzki D; Kickingereder P; Hentschel B; Felsberg J; Herrlinger U; Schackert G; Tonn JC; Westphal M; Sabel M; Schlegel U; Wick W; Pietsch T; Reifenberger G; Loeffler M; Bendszus M; Weller M
Neurology; 2017 Apr; 88(15):1422-1430. PubMed ID: 28298550
[TBL] [Abstract][Full Text] [Related]
28. Temozolomide in combination with BCNU before and after radiotherapy in patients with inoperable newly diagnosed glioblastoma multiforme.
Barrié M; Couprie C; Dufour H; Figarella-Branger D; Muracciole X; Hoang-Xuan K; Braguer D; Martin PM; Peragut JC; Grisoli F; Chinot O
Ann Oncol; 2005 Jul; 16(7):1177-84. PubMed ID: 15857844
[TBL] [Abstract][Full Text] [Related]
29. Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles.
Barbagallo GM; Paratore S; Caltabiano R; Palmucci S; Parra HS; Privitera G; Motta F; Lanzafame S; Scaglione G; Longo A; Albanese V; Certo F
Neurosurg Focus; 2014 Dec; 37(6):E4. PubMed ID: 25434389
[TBL] [Abstract][Full Text] [Related]
30. Postoperative radiotherapy and concomitant temozolomide for elderly patients with glioblastoma.
Gerstein J; Franz K; Steinbach JP; Seifert V; Fraunholz I; Weiss C; Rödel C
Radiother Oncol; 2010 Dec; 97(3):382-6. PubMed ID: 20850883
[TBL] [Abstract][Full Text] [Related]
31. Clinical outcome of concomitant chemoradiotherapy followed by adjuvant temozolomide therapy for glioblastaomas: single-center experience.
Jeon HJ; Kong DS; Park KB; Lee JI; Park K; Kim JH; Kim ST; Lim DH; Kim WS; Nam DH
Clin Neurol Neurosurg; 2009 Oct; 111(8):679-82. PubMed ID: 19640635
[TBL] [Abstract][Full Text] [Related]
32. Hypofractionated versus standard radiation therapy in combination with temozolomide for glioblastoma in the elderly: a meta-analysis.
Lu VM; Kerezoudis P; Brown DA; Burns TC; Quinones-Hinojosa A; Chaichana KL
J Neurooncol; 2019 Jun; 143(2):177-185. PubMed ID: 30919157
[TBL] [Abstract][Full Text] [Related]
33. A Phase 2 Study of Concurrent Radiation Therapy, Temozolomide, and the Histone Deacetylase Inhibitor Valproic Acid for Patients With Glioblastoma.
Krauze AV; Myrehaug SD; Chang MG; Holdford DJ; Smith S; Shih J; Tofilon PJ; Fine HA; Camphausen K
Int J Radiat Oncol Biol Phys; 2015 Aug; 92(5):986-992. PubMed ID: 26194676
[TBL] [Abstract][Full Text] [Related]
34. The efficacy and safety of radiotherapy with adjuvant temozolomide for glioblastoma: A meta-analysis of randomized controlled studies.
Wang Y; Feng Y
Clin Neurol Neurosurg; 2020 Sep; 196():105890. PubMed ID: 32623215
[TBL] [Abstract][Full Text] [Related]
35. Impact of angiogenic inhibition in the treatment of newly diagnosed and recurrent glioblastoma: a meta-analysis based on randomized controlled trials.
Lan XY; Li D; Li S; Zhong LZ; Zhao H; Xi YL; Sun ZW
Eur Rev Med Pharmacol Sci; 2022 May; 26(10):3522-3533. PubMed ID: 35647833
[TBL] [Abstract][Full Text] [Related]
36. Bevacizumab, temozolomide, and radiotherapy for newly diagnosed glioblastoma: comprehensive safety results during and after first-line therapy.
Saran F; Chinot OL; Henriksson R; Mason W; Wick W; Cloughesy T; Dhar S; Pozzi E; Garcia J; Nishikawa R
Neuro Oncol; 2016 Jul; 18(7):991-1001. PubMed ID: 26809751
[TBL] [Abstract][Full Text] [Related]
37. Carbon ion radiotherapy boost in the treatment of glioblastoma: a randomized phase I/III clinical trial.
Kong L; Gao J; Hu J; Lu R; Yang J; Qiu X; Hu W; Lu JJ
Cancer Commun (Lond); 2019 Feb; 39(1):5. PubMed ID: 30786916
[TBL] [Abstract][Full Text] [Related]
38. A multicenter phase II study of temozolomide plus disulfiram and copper for recurrent temozolomide-resistant glioblastoma.
Huang J; Chaudhary R; Cohen AL; Fink K; Goldlust S; Boockvar J; Chinnaiyan P; Wan L; Marcus S; Campian JL
J Neurooncol; 2019 May; 142(3):537-544. PubMed ID: 30771200
[TBL] [Abstract][Full Text] [Related]
39. Bevacizumab in combination with radiotherapy and temozolomide for patients with newly diagnosed glioblastoma multiforme.
van Linde ME; Verhoeff JJ; Richel DJ; van Furth WR; Reijneveld JC; Verheul HM; Stalpers LJ
Oncologist; 2015 Feb; 20(2):107-8. PubMed ID: 25582142
[TBL] [Abstract][Full Text] [Related]
40. Neoadjuvant bevacizumab and irinotecan versus bevacizumab and temozolomide followed by concomitant chemoradiotherapy in newly diagnosed glioblastoma multiforme: A randomized phase II study.
Hofland KF; Hansen S; Sorensen M; Engelholm S; Schultz HP; Muhic A; Grunnet K; Ask A; Costa JC; Kristiansen C; Thomsen C; Poulsen HS; Lassen U
Acta Oncol; 2014 Jul; 53(7):939-44. PubMed ID: 24456504
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
